Larimar Therapeutics Inc

LRMR12 Dec 2024
Healthcare
$6.55
-0.01 (-0.99%)
Lowest Today
$6.06
Highest Today
$6.58
Today’s Open
$6.55
Prev. Close
$6.57
52 Week High
$13.68
52 Week Low
$3.75
To Invest in Larimar Therapeutics Inc

Larimar Therapeutics Inc

Healthcare
LRMR12 Dec 2024
-0.01 (-0.99%)
1M
3M
6M
1Y
5Y
Low
$6.06
Day’s Range
High
$6.58
6.06
52 Week Low
$3.74
52-Week Range
52 Week High
$13.68
3.74
1 Day
-
1 Week
+8.23%
1 month return
-29.73%
3 month return
-12.28%
6 month return
-29.8%
1 Year return
+79.01%
3 Years return
-29.35%
5 Years return
-34.81%
10 Years return
-
Institutional Holdings
Deerfield Management Co
33.28
RA Capital Management, LLC
9.47
HHG PLC
8.72
Goldman Sachs Group Inc
6.66
Blue Owl Capital Holdings LP
6.53
BlackRock Inc
4.91
Vanguard Group Inc
3.6

Market Status

Fundamentals
Market Cap
431.33 mln
PB Ratio
2.08
PE Ratio
0
Enterprise Value
213.85 mln
Total Assets
95.94 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Organisation
Larimar Therapeutics Inc
Employees
42
Industry
Biotechnology
CEO
Dr. Carole S. Ben-Maimon M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities